Before revision:  We envision our approach to transform in silico anticancer drug design by increasing success rates in lead compound discovery via leveraging the biomolecular characteristics of the disease  .
After revision:  We envision our approach to transform in silico anticancer drug design by leveraging the biomolecular characteristics of the disease .